Skip to main content

Table 2 Injection characteristics in study groups

From: Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema

 Group 1 (42 eyes)Group 2 (14 eyes)
 Subgroup 1ASubgroup 1BBaseline to 1st switch1st switch to 2nd switchAfter 2nd switch
Type of treatmentAvastin6 (25%)3 (16.7%)
Lucentis9 (37.5%)8 (44.4%)
Eylea9 (37.5%)7 (38.9%)
 p = 0.86
Duration of treatment18 months42 eyes (100%)34.3 ± (16.1)50.8 ± (35)60.2 ± (31.4)
24 months32 eyes (76%)
Number of injections, mean (SD) 11.8 ± (3.2)13.1 ± (3.1)4.9 ± (2)6.9 ± (4)3.8 ± (1)
Interval between injections, mean (SD) 1.8 ± (0.2)1.7 ± (0.3)1.6 ± (0.3)1.7 ± (0.4)1.6 ± (0.3)